The interaction between cluster of differentiation 47(CD47)and signal regulatory proteinα(SiRPa)protects healthy cells from macrophage attack,which is crucial for maintain-ing immune homeostasis.Overexpression of CD4...The interaction between cluster of differentiation 47(CD47)and signal regulatory proteinα(SiRPa)protects healthy cells from macrophage attack,which is crucial for maintain-ing immune homeostasis.Overexpression of CD47 occurs widely across various tumor cell types and transmits the"don't eat me"signal to macrophages to avoid phagocytosis through binding to SIRPa.Blockade of the CD47-SIRPa axis is therefore a promising approach for cancer treat-ment.Lymphoma is the most common hematological malignancy and is an area of unmet clin-ical need.This review mainly described the current strategies targeting the CD47-SIRPa axis,including antibodies,SiRPaFc fusion proteins,small molecule inhibitors,and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma.展开更多
肿瘤免疫治疗在结直肠癌(colorectal cancer,CRC)患者治疗中的成功使得肿瘤疫苗、单抗、过继T细胞疗法(adoptive cell transfer therapy,ACT)治疗、免疫检查点抑制剂等免疫治疗方式引起广泛关注。目前,应用前景较好的免疫治疗就是包括...肿瘤免疫治疗在结直肠癌(colorectal cancer,CRC)患者治疗中的成功使得肿瘤疫苗、单抗、过继T细胞疗法(adoptive cell transfer therapy,ACT)治疗、免疫检查点抑制剂等免疫治疗方式引起广泛关注。目前,应用前景较好的免疫治疗就是包括程序性死亡受1/程序性死亡配体1(programmed death receptor 1/programmed death ligand 1,PD-1/PD-L1)和细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte antigen 4,CTLA-4)抑制剂在内的免疫检查点抑制剂。PD-1/PD-L1和CTLA-4抑制剂仅在失配修复缺陷的CRC患者中显示出较好的疗效,而对于其他类型的CRC,靶向CD47-SIRPα免疫检查点抑制剂将是未来治疗热点。文章就近年CRC免疫治疗及免疫检查点CD47的研究进展进行综述。展开更多
基金supported by the National Key Research and Development Program of China(No.2020YFA0803201)the National Natural Science Foundation of China(No.31830053,31920103007,22207084)the Fundamental ResearchFunds fortheCornellUniversity(No.22120220463).
文摘The interaction between cluster of differentiation 47(CD47)and signal regulatory proteinα(SiRPa)protects healthy cells from macrophage attack,which is crucial for maintain-ing immune homeostasis.Overexpression of CD47 occurs widely across various tumor cell types and transmits the"don't eat me"signal to macrophages to avoid phagocytosis through binding to SIRPa.Blockade of the CD47-SIRPa axis is therefore a promising approach for cancer treat-ment.Lymphoma is the most common hematological malignancy and is an area of unmet clin-ical need.This review mainly described the current strategies targeting the CD47-SIRPa axis,including antibodies,SiRPaFc fusion proteins,small molecule inhibitors,and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma.
文摘肿瘤免疫治疗在结直肠癌(colorectal cancer,CRC)患者治疗中的成功使得肿瘤疫苗、单抗、过继T细胞疗法(adoptive cell transfer therapy,ACT)治疗、免疫检查点抑制剂等免疫治疗方式引起广泛关注。目前,应用前景较好的免疫治疗就是包括程序性死亡受1/程序性死亡配体1(programmed death receptor 1/programmed death ligand 1,PD-1/PD-L1)和细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte antigen 4,CTLA-4)抑制剂在内的免疫检查点抑制剂。PD-1/PD-L1和CTLA-4抑制剂仅在失配修复缺陷的CRC患者中显示出较好的疗效,而对于其他类型的CRC,靶向CD47-SIRPα免疫检查点抑制剂将是未来治疗热点。文章就近年CRC免疫治疗及免疫检查点CD47的研究进展进行综述。